Chemotherapy-related cognitive dysfunction: current animal studies and future directions.
Cognitive impairment is a potential long-term side effect of adjuvant chemotherapy that can have a major impact on the quality of life of cancer survivors. There is a growing number of preclinical studies addressing this issue, thereby extending our knowledge of the mechanisms underlying chemotherapy-induced neurotoxicity. In this review, we will summarize the recent advances and important findings presented in these studies. Emerging challenges, such as the development of neuroprotective strategies, and the role of the blood-brain barrier on cognitive impairment will be described and future directions in this field of investigation will be outlined.
Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, R.seigers@nki.nl.
R
R
Seigers
S B
SB
Schagen
O
O
Van Tellingen
J
J
Dietrich
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology*; D004195:Disease Models, Animal; D019317:Evidence-Based Medicine; D005544:Forecasting; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D000970:Antineoplastic Agents